Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadekinig alfa for CAR T Cell Related CRS and HLH-like Syndrome
NCT05306080Phase 1Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Apr 2022
- Primary completion
- Jan 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tadekinig alfa in cytokine release syndrome (CRS) and hemophagocytic lymphohistiocytosis (HLH), sponsored by University of Pennsylvania. Primary endpoint: Safety and Feasibility of administering investigational rescue therapies at 28 days. Started Apr 2022; status: recruiting.
02
Drugs
tadekinig alfa
03
Conditions
cytokine release syndrome (CRS)hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT05306080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05306080.